Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research upgraded shares of Trevena from a “sell” rating to a “hold” rating in a research note on Wednesday, February 2nd.

Shares of TRVN stock opened at $0.39 on Thursday. The company has a 50 day moving average price of $0.46 and a 200-day moving average price of $0.66. Trevena has a 52 week low of $0.36 and a 52 week high of $2.20. The firm has a market capitalization of $64.92 million, a PE ratio of -1.27 and a beta of 2.27.

Trevena (NASDAQ:TRVN – Get Rating) last announced its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Trevena had a negative net margin of 7,771.74% and a negative return on equity of 62.36%. During the same period last year, the firm earned ($0.08) earnings per share. Sell-side analysts forecast that Trevena will post -0.37 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its position in Trevena by 454.1% during the third quarter. BNP Paribas Arbitrage SA now owns 34,896 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 28,598 shares during the period. Bank of America Corp DE boosted its position in shares of Trevena by 48.1% in the second quarter. Bank of America Corp DE now owns 34,607 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 11,243 shares during the period. Two Sigma Advisers LP bought a new position in shares of Trevena in the third quarter worth approximately $60,000. Invesco Ltd. bought a new position in shares of Trevena in the second quarter worth approximately $73,000. Finally, Barclays PLC bought a new position in shares of Trevena in the third quarter worth approximately $83,000. Institutional investors own 22.62% of the company’s stock.

Trevena Company Profile (Get Rating)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Read More